ATLANTA -- An investigational quadruple receptor agonist led to a substantial reduction in total body weight with minimal ...

Patients with type 2 diabetes who use GLP-1 receptor agonists have a significantly lower risk for lung cancer than those who ...

The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or ...

An investigational triple agonist that targets fibroblast growth factor 21, glucagon and GLP-1 receptors cut triglyceride ...

Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

A once-daily oral quadruple receptor agonist induced up to 13.8% weight loss at 13 weeks among adults with overweight or ...

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...

Eli Lilly (LLY) stock is in focus as the company's amylin receptor agonist eloralintide helped patients lose up to 20% body ...

Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of ...

Administered once weekly via subcutaneous injection, semaglutide offers efficacy and durability advantages across multiple ...